|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM319759695 |
| 003 |
DE-627 |
| 005 |
20231225172131.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108661
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1065.xml
|
| 035 |
|
|
|a (DE-627)NLM319759695
|
| 035 |
|
|
|a (NLM)33412295
|
| 035 |
|
|
|a (PII)S1521-6616(20)30821-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a De Groot, Anne S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.06.2021
|
| 500 |
|
|
|a Date Revised 11.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Identification of T cell epitopes that are recognized by Tregs may elucidate the relative contributions of thymic Tregs and induced Tregs to control of autoimmune diseases and allergy. One such T regulatory cell epitope or 'Tregitope', derived from blood Factor V, is described here. Tregs responding to Tregitope FV621 are potent suppressors of CD4+ T effector responses to Tetanus Toxoid in an in vitro bystander suppression assay, strongly inhibit proliferation of effector CD8+ T cells, down-modulate CD86 and HLA DR on antigen-presenting cells, and enhance expression of granzyme B in Tregs. Tregitope FV621 also suppresses anti-OVA immune responses in vivo. The immunomodulatory effect of Tregitope FV621 is enhanced when conjugated to albumin, suggesting that the short half-life of Tregitope peptides can be prolonged. The in silico tools used to prospectively identify the FV Tregitope described here, when combined with in vitro /in vivo validating assays, may facilitate future Tregitope discoveries
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-drug-antibody (ADA)
|
| 650 |
|
4 |
|a Factor V (FV)
|
| 650 |
|
4 |
|a Factor VIII (FVIII)
|
| 650 |
|
4 |
|a Hemophilia
|
| 650 |
|
4 |
|a Immunogenicity
|
| 650 |
|
4 |
|a Inhibitor
|
| 650 |
|
4 |
|a Regulatory T cell epitope
|
| 650 |
|
4 |
|a Tolerance
|
| 650 |
|
4 |
|a Treg
|
| 650 |
|
4 |
|a Tregitope
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Epitopes, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Tetanus Toxoid
|2 NLM
|
| 650 |
|
7 |
|a Factor V
|2 NLM
|
| 650 |
|
7 |
|a 9001-24-5
|2 NLM
|
| 650 |
|
7 |
|a Ovalbumin
|2 NLM
|
| 650 |
|
7 |
|a 9006-59-1
|2 NLM
|
| 700 |
1 |
|
|a Rosenberg, Amy S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miah, S M Shahjahan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Skowron, Gail
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roberts, Brian J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lélias, Sandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Terry, Frances E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martin, William D
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 224(2021) vom: 04. März, Seite 108661
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:224
|g year:2021
|g day:04
|g month:03
|g pages:108661
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108661
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 224
|j 2021
|b 04
|c 03
|h 108661
|